Registration Study Sarcoma
Registration Study on Bone and Soft Tissue Sarcoma - An Observational Cohort Study -
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The main objectives of this project are:
- To improve the knowledge and therefore the treatment care, in patients with bone or soft tissue sarcoma in the Netherlands
- To start an observational cohort study of bone and soft tissue sarcoma patients from their primary diagnosis until death
- To prospectively and retrospectively collect data on medical history, co-morbidities, baseline clinical parameters, imaging results, pathology results, tumor characteristics, treatment, treatment outcomes, functional outcome, cosmetic outcome, hospital stays and interventions.
- To collect data on health related quality of life and work ability, to collect data on patient reported outcomes measures.
To create a continuous basis for a large variety of research purposes including:
- Prognostic and predictive research
- Health care policies and cost-effectiveness studies
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Pètra Braam, MD/PhD
- Phone Number: +31243614515
- Email: p.braam@radboudumc.nl
Study Contact Backup
- Name: Ingrid Desar, MD/PhD
- Phone Number: +31243610353
- Email: ingrid.desar@radboudumc.nl
Study Locations
-
-
-
Arnhem, Netherlands
- Recruiting
- Radiotherapiegroep
-
Contact:
- Marjan van Hezewijk, MD/PhD
-
Nijmegen, Netherlands
- Recruiting
- Radboudumc
-
Contact:
- Pètra Braam, MD/PhD
-
Contact:
- Ingrid Desar, MD/PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histologically proven bone or soft tissue sarcoma, excluding Gastrointestinal Stromal Tumours
Exclusion Criteria:
- Altered mental status that would prohibit the understanding of and giving of informed consent
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression free survival
Time Frame: up to 10 years
|
PFS
|
up to 10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health related quality of life
Time Frame: up to 5 years
|
measured by EORTC QOL questionnaires
|
up to 5 years
|
|
grade 3/4 serious adverse events
Time Frame: up to 5 years
|
AE
|
up to 5 years
|
|
Disease free survival
Time Frame: up to 10 years
|
DFS
|
up to 10 years
|
|
Overall survival
Time Frame: up to 10 years
|
OS
|
up to 10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NL69559.091.19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.